Download PDF
Semin Reprod Med 2002; 20(4): 317-326
DOI: 10.1055/s-2002-36706
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Regulation of Gonadotropin Secretion: Implications for Polycystic Ovary Syndrome

Christopher R. McCartney, Christine A. Eagleson, John C. Marshall
  • Center for Research in Reproduction, Division of Endocrinology, Department of Internal Medicine, University of Virginia Health System, Charlottesville, Virginia
Further Information

Publication History

Publication Date:
21 January 2003 (online)

    Permissions and Reprints

ABSTRACT

Polycystic ovary syndrome (PCOS) is a disorder characterized by hyperandrogenism and chronic anovulation. Although the etiology of PCOS is unknown, perturbations of gonadotropin secretion are one of the hallmarks of this disorder. In normal menstrual physiology, the monotropic rise of plasma follicle-stimulating hormone (FSH) during the luteal-follicular transition is critical for follicular development and subsequent ovulation. One of the mechanisms by which FSH is differentially synthesized involves the luteal slowing of gonadotropin-releasing hormone (GnRH) pulse frequency by ovarian steroids. In PCOS, plasma leutinizing hormone (LH) is commonly increased, FSH is typically in the lower follicular range, and LH (and by inference GnRH) pulse frequency is persistently rapid at approximately one LH pulse per hour. The etiology of the neuroendocrine abnormalities in PCOS remain unclear; however, recent studies have revealed decreased sensitivity of the GnRH pulse generator to inhibition by ovarian steroids, particularly progesterone. This abnormality is reversed by the androgen receptor antagonist flutamide, suggesting that elevated androgen levels may alter the sensitivity of the hypothalamic GnRH pulse generator to steroid inhibition and lead to enhanced LH secretion. As such, women with PCOS require higher levels of progesterone to slow the frequency of GnRH pulse secretion, resulting in inadequate FSH synthesis and persistent LH stimulation of ovarian androgens. The decreased sensitivity of the GnRH pulse generator may help to explain the genesis of PCOS during puberty. In normal early puberty, sleep-entrained increases in LH stimulate ovarian steroids, which subsequently suppress LH frequency and amplitude during the subsequent day. In hyperandrogenemic girls destined to develop PCOS, this nocturnal increase in ovarian steroids may not be adequate to suppress the GnRH pulse generator, leading to a persistently rapid LH pulse frequency, impaired FSH production, and inadequate follicular development.

KEYWORD

Gonadotropins - LH - polycystic ovary syndrome - menstrual cycle - flutamide

REFERENCES

  • 1 Dunaif A. Insulin resistance and polycystic ovary syndrome: mechanisms and implications for pathogenesis.  Endocr Rev . 1997;  18 774-800
    CrossrefPubMedGoogle Scholar
  • 2 Franks S. Polycystic ovary syndrome.  N Engl J Med . 1995;  333 853-861
    CrossrefPubMedGoogle Scholar
  • 3 Taylor A E. Polycystic ovary syndrome.  Endocrinol Metab Clin North Am . 1998;  27 877-902
    CrossrefPubMedGoogle Scholar
  • 4 Marshall J C, Eagleson C A. Neuroendocrine aspects of polycystic ovary syndrome.  Endocrinol Metab Clin North Am . 1999;  28 295-324
    CrossrefPubMedGoogle Scholar
  • 5 Ehrmann D A, Barnes R B, Rosenfield R L. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.  Endocr Rev . 1995;  16 322-353
    CrossrefPubMedGoogle Scholar
  • 6 Steingold K, De Ziegler D, Cedars M. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease.  J Clin Endocrinol Metab . 1987;  65 773-778
    CrossrefPubMedGoogle Scholar
  • 7 Marshall J C. Estrogen-progestagen therapy in the management of the polycystic ovary syndrome.  J Endocrinol Invest . 1998;  21 618-622
    PubMedGoogle Scholar
  • 8 Hall J E. Polycystic ovarian disease as a neuroendocrine disorder of the female reproductive axis.  Endocrinol Metab Clin North Am . 1993;  22 75-92
    PubMedGoogle Scholar
  • 9 Marshall J C, Case G D, Valk T W, Corley K P, Sauder S E, Kelch R P. Selective inhibition of FSH secretion by estradiol: a mechanism for modulation of gonadotropin responses to low dose pulses of gonadotropin-releasing hormone.  J Clin Invest . 1983;  71 248-258
    PubMedGoogle Scholar
  • 10 Hayes F J, Hall J E, Boepple P A, Crowley W F. Differential control of gonadotropin secretion in the human: endocrine role of inhibin.  J Clin Endocrinol Metab . 1998;  83 1835-1841
    CrossrefPubMedGoogle Scholar
  • 11 Muttukrishna S, Fowler P A, George L, Groome N P, Knight P G. Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy.  J Clin Endocrinol Metab . 1996;  81 3328-3334
    CrossrefPubMedGoogle Scholar
  • 12 Wildt L, Hausler A, Marshall G. Frequency and amplitude of gonadotropin-releasing hormone stimulation and gonadotropin secretion in the rhesus monkey.  Endocrinol . 1981;  109 376-385
    CrossrefPubMedGoogle Scholar
  • 13 Clarke I J, Cummins J T, Findlay J K, Burman K J, Doughton B W. Effects on plasma luteinizing hormone and follicle-stimulating hormone of varying the frequency and amplitude of gonadotropin-releasing hormone pulses in ovariectomized ewes with hypothalamo-pituitary disconnection.  Neuroendocrinol . 1984;  39 214-221
    PubMedGoogle Scholar
  • 14 Haisenleder D J, Dalkin A C, Marshall J C. Regulation of gonadotropin gene expression. In: Knobil E, Neill J, eds. The Physiology of Reproduction 2nd ed. New York: Raven Press 1994: 1793
    Google Scholar
  • 15 Dalkin A C, Haisenleder D J, Gilrain J T, Aylor K, Yasin M, Marshall J C. Gonadotropin-releasing hormone regulation of gonadotropin subunit gene expression in female rats: actions on follicle-stimulating hormone beta messenger ribonucleic acid (mRNA) involve differential expression of pituitary activin (beta-B) and follistatin mRNAs.  Endocrinology . 1999;  140 903-908
    CrossrefPubMedGoogle Scholar
  • 16 Kirk S E, Dalkin A C, Yasin M, Haisenleder D J, Marshall J C. Gonadotropin-releasing hormone pulse frequency regulates expression of pituitary follistatin messenger ribonucleic acid: a mechanism for differential gonadotrope function.  Endocrinology . 1994;  135 876-880
    CrossrefPubMedGoogle Scholar
  • 17 Reame N, Sauder S E, Kelch R P, Marshall J C. Pulsatile gonadotropin secretion during the human menstrual cycle: evidence for altered frequency of gonadotropin-releasing hormone secretion.  J Clin Endocrinol Metab . 1984;  59 328-337
    PubMedGoogle Scholar
  • 18 Filicori M, Santoro N, Merriam G R, Crowley W F. Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle.  J Clin Endocrinol Metab . 1986;  62 1136-1144
    PubMedGoogle Scholar
  • 19 Backstrom C T, McNeilly A S, Leask R M, Baird D T. Pulsatile secretion of LH, FSH, prolactin, estradiol, and progesterone during the human menstrual cycle.  Clin Endocrinol (Oxf) . 1982;  7 29-42
    PubMedGoogle Scholar
  • 20 Filicori M, Butler J P, Crowley W F. Neuroendocrine regulation of the corpus luteum in the human.  J Clin Invest . 1984;  73 1638-1647
    CrossrefPubMedGoogle Scholar
  • 21 Rossmanith W G, Liu C H, Laughlin G A, Mortola J F, Suh B Y, Yen S S. Relative changes in LH pulsatility during the menstrual cycle: using data from hypogonadal women as a reference point.  Clin Endocrinol (Oxf) . 1990;  32 647-660
    PubMedGoogle Scholar
  • 22 Marshall J C, Dalkin A C, Haisenleder D J, Paul S J, Ortolano G A, Kelch R P. Gonadotropin-releasing hormone pulses: regulators of gonadotropin synthesis and ovulatory cycles.  Recent Prog Horm Res . 1991;  47 155-189
    PubMedGoogle Scholar
  • 23 Sollenberger M J, Carlsen E C, Johnson M L, Veldhuis J D, Evans W S. Specific physiological regulation of LH secretory events throughout the human menstrual cycle: new insights into the pulsatile mode of gonadotropin release.  J Neuroendo . 1990;  2 845-852
    PubMedGoogle Scholar
  • 24 Soules M R, Steiner R A, Clifton D K, Cohen N L, Aksel S, Bremner W J. Progesterone modulation of pulsatile luteinizing hormone secretion in normal women.  J Clin Endocrinol Metab . 1984;  58 378-383
    PubMedGoogle Scholar
  • 25 Goodman R L, Bittman E L, Foster D L, Karsch F J. The endocrine basis of the synergistic suppression of luteinizing hormone by estradiol and progesterone.  Endocrinology . 1981;  109 1414-1417
    PubMedGoogle Scholar
  • 26 Nippoldt T B, Reame N E, Kelch R P, Marshall J C. The roles of estradiol and progesterone in decreasing luteinizing hormone pulse frequency in the luteal phase of the menstrual cycle.  J Clin Endocrinol Metab . 1989;  69 67-76
    PubMedGoogle Scholar
  • 27 MacLusky N J, McEwen B S. Oestrogen modulates progestin receptor concentrations in some rat brain regions but not in others.  Nature . 1978;  274 276-278
    CrossrefPubMedGoogle Scholar
  • 28 Romano G J, Krust A, Pfaff D W. Expression and estrogen regulation of progesterone receptor mRNA in neurons of the mediobasal hypothalamus: an in situ hybridization study [erratum appears in Mol Endocrinol 1989;3:1860].  Mol Endocrinol . 1989;  3 1295-1300
    PubMedGoogle Scholar
  • 29 Wehrenberg W B, Wardlaw S L, Frantz A, Ferin M. β-endorphin in hypophyseal portal blood: variations throughout the menstrual cycle.  Endocrinol . 1982;  111 879-881
    PubMedGoogle Scholar
  • 30 Gindoff P R, Jewelewicz R, Hembree W, Wardlaw S, Ferin M. Sustained effects of opioid antagonism during the normal human luteal phase.  J Clin Endocrinol Metab . 1988;  66 1000-1004
    PubMedGoogle Scholar
  • 31 Casper R F, Alapin-Rubillovitz S. Progestins increase endogenous opioid peptide activity in postmenopausal women.  J Clin Endocrinol Metab . 1985;  60 34-36
    CrossrefPubMedGoogle Scholar
  • 32 Wardlaw S L, Wehrenberg W B, Ferin M, Antunes J L, Frantz A G. Effect of sex steroids on β-endorphin in hypophyseal portal blood.  J Clin Endocrinol Metab . 1982;  55 877-881
    CrossrefPubMedGoogle Scholar
  • 33 Welt C K, Martin K A, Taylor A E. Frequency modulation of follicle-stimulating hormone (FSH) during the luteal-follicular transition: evidence for FSH control of inhibin B in normal women.  J Clin Endocrinol Metab . 1997;  82 2645-2652
    CrossrefPubMedGoogle Scholar
  • 34 McCartney C R, Gingrich M B, Hu Y, Evans W S, Marshall J C. Hypothalmic regulation of cyclic ovulation: evidence that the increase in gonadotropin-releasing hormone pulse frequency during the follicular phase reflects the gradual loss of the restraining effects of progesterone.  J Clin Endocrinol Metab . 2002;  87 2194-2200
    CrossrefPubMedGoogle Scholar
  • 35 Conway G S, Honour J W, Jacobs H S. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine, and ultrasound features in 556 patients.  Clin Endocrinol (Oxf) . 1989;  30 459-470
    PubMedGoogle Scholar
  • 36 Franks S. Polycystic ovary syndrome: a changing perspective.  Clin Endocrinol (Oxf) . 1989;  31 87-120
    CrossrefPubMedGoogle Scholar
  • 37 Rebar R, Judd H L, Yen S SC. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.  J Clin Invest . 1976;  57 1320-1329
    CrossrefPubMedGoogle Scholar
  • 38 Taylor A E, McCourt B, Martin K A. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome.  J Clin Endocrinol Metab . 1997;  82 2248-2256
    CrossrefPubMedGoogle Scholar
  • 39 Yen S SC, Lasley B L, Wang C F. The operating characteristics of the hypothalamic-pituitary system during the menstrual cycle and observation of the biological action of somatostatin.  Rec Prog Hormone Res . 1975;  31 361-363
    PubMedGoogle Scholar
  • 40 Waldstreicher J, Santoro N F, Hall J E. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovary syndrome.  J Clin Endocrinol Metab . 1988;  66 165-172
    CrossrefPubMedGoogle Scholar
  • 41 Buvat J, Buvat-Herbaut M, Marcolin G. A double-blind controlled study of the hormonal and clinical effects of bromocriptine in the polycystic ovarian syndrome.  J Clin Endocrinol Metab . 1986;  63 119-124
    PubMedGoogle Scholar
  • 42 Murdoch A P, McClean K G, Watson M J. Treatment of hirsutism in polycystic ovary syndrome with bromocriptine.  Br J Obstet Gynecol . 1987;  94 358-365
    PubMedGoogle Scholar
  • 43 Barnes R B, Lobo R A. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation.  J Clin Endocrinol Metab . 1985;  61 779-782
    PubMedGoogle Scholar
  • 44 Cumming D C, Reid R L, Quigley M E. Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome.  Clin Endocrinol (Oxf) . 1984;  20 643-648
    CrossrefPubMedGoogle Scholar
  • 45 Berga S L, Yen S SC. Opioidergic regulation of LH pulsatility in women with PCOS.  Clin Endocrinol (Oxf) . 1989;  30 177-184
    PubMedGoogle Scholar
  • 46 Lobo R A, Granger L R, Wellington L P. Psychological stress and increases in urinary norepinephrine metabolites, platelet serotonin, and adrenal androgens in women with polycystic ovary syndrome.  Am J Obstet Gynecol . 1983;  145 496-503
    CrossrefPubMedGoogle Scholar
  • 47 Paradisi R, Venturoli S, Capelli M. Effects of alpha-adrenergic blockade on pulsatile LH, FSH and prolactin secretion in polycystic ovary syndrome.  J Clin Endocrinol Metab . 1987;  65 841-846
    PubMedGoogle Scholar
  • 48 Rosen G F, Lobo R A. Further evidence against dopamine deficiency as a cause of inappropriate gonadotropin secretion in patients with polycystic ovary syndrome.  J Clin Endocrinol Metab . 1987;  65 891-895
    PubMedGoogle Scholar
  • 49 Yen S SC, Chaney C, Judd H L. Functional aberrations of the hypothalamic-pituitary system in PCOS: a consideration of pathogenesis. In: James VHT, ed. The Endocrine Function of the Human Ovary New York: Academic Press 1976: 273
    Google Scholar
  • 50 Chang R J, Mandel F P, Lu J K, Judd H L. Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease.  J Clin Endocrinol Metab . 1982;  54 490-494
    PubMedGoogle Scholar
  • 51 Morales A J, Laughlin G A, Butzow T. Insulin, somatotrophic, and luteinizing hormone axes in non-obese and obese women with polycystic ovary syndrome: common and distinct features.  J Clin Endocrinol Metab . 1996;  81 2854-2864
    CrossrefPubMedGoogle Scholar
  • 52 Barbieri R L, Markis A, Randall R W, Daniels G, Kistner R W, Ryan K J. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism.  J Clin Endocrinol Metab . 1986;  62 904-910
    CrossrefPubMedGoogle Scholar
  • 53 Nestler J E, Jakubowicz D J, de Vargas F A. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system.  J Clin Endocrinol Metab . 1998;  83 2001-2005
    CrossrefPubMedGoogle Scholar
  • 54 Poretsky L, Piper B. Insulin resistance, hypersecretion of LH and a dual defect hypothesis for the pathogenesis of PCOS.  Obstet Gynecol . 1994;  84 613-621
    PubMedGoogle Scholar
  • 55 Nestler J E, Jacubowicz D J. Decreases in ovarian cytochrome P450 c17 activity and serum free testosterone after reduction of insulin secretion in PCOS.  N Engl J Med . 1996;  335 617-623
    CrossrefPubMedGoogle Scholar
  • 56 Dunaif A, Scott D, Finegood D. The insulin sensitizing agent Troglitazone improves metabolic and reproductive abnormalities in PCOS.  J Clin Endocrinol Metab . 1996;  81 3299-3306
    CrossrefPubMedGoogle Scholar
  • 57 Acbay O, Gundogdu S. Can metformin reduce insulin resistance in PCOS.  Fertil Steril . 1996;  65 946-949
    PubMedGoogle Scholar
  • 58 Melrose P, Gross L. Steroids effect the secretory modalities of GnRH release.  Endocrinology . 1987;  121 190-199
    PubMedGoogle Scholar
  • 59 Barnes R B, Rosenfield R L, Ehrmann D A. Ovarian hyperandrogenism as a result of congenital adrenal viralizing disorders: evidence for perinatal masculinization of neuroendocrine function in women.  J Clin Endocrinol Metab . 1994;  79 1328-1333
    CrossrefPubMedGoogle Scholar
  • 60 Dunaif A. Do androgens directly regulate gonadotropin secretion in the polycystic ovary syndrome?.  J Clin Endocrinol Metab . 1986;  63 215-221
    PubMedGoogle Scholar
  • 61 Serafini P, Silva P D, Paulson R J. Acute modulation of hypothalamic-pituitary axis by intravenous testosterone in normal women.  Am J Obstet Gynecol . 1986;  155 1288-1292
    PubMedGoogle Scholar
  • 62 Spinder T, Spijkstra J J, Van Den Tweel. The effect of long term testosterone administration on pulsatile LH secretion and ovarian histology in eugonadal female to male transsexuals.  J Clin Endocrinol Metab . 1989;  69 151-157
    PubMedGoogle Scholar
  • 63 Pastor C L, Griffin-Korf M L, Aloi J A. Polycystic ovarian syndrome: evidence for reduced sensitivity of the GnRH pulse generator to inhibition by estradiol and progesterone.  J Clin Endocrinol Metab . 1998;  83 582-590
    CrossrefPubMedGoogle Scholar
  • 64 Daniels T L, Berga S L. Resistance of GnRH drive to sex steroid induced suppression in hyperandrogenemic anovulation.  J Clin Endocrinol Metab . 1997;  82 4179-4183
    CrossrefPubMedGoogle Scholar
  • 65 Eagleson C A, Gingrich M B, Pastor C L. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.  J Clin Endocrinol Metab . 2000;  85 4047-4052
    CrossrefPubMedGoogle Scholar
  • 66 Dumesic D A, Abbott D H, Eisner J R, Goy R W. Prenatal exposure of female rhesus monkeys to testosterone propionate increases serum luteinizing hormone levels in adulthood.  Fertil Steril . 1997;  67 155-163
    CrossrefPubMedGoogle Scholar
  • 67 Robinson J E, Forsdike R A, Taylor J A. In utero exposure of female lambs to testosterone reduces sensitivity of the gonadotropin-releasing hormone neuronal network to inhibition by progesterone.  Endocrinology . 1999;  140 5797-5805
    CrossrefPubMedGoogle Scholar
  • 68 Venturoli S, Porcu E, Fabri R. Longitudinal evaluation of different gonadotropin pulsatile patterns in anovulatory cycles of young girls.  J Clin Endocrinol Metab . 1992;  74 836-841
    CrossrefPubMedGoogle Scholar
  • 69 Apter D, Vihko R. Endocrine determinants of fertility: serum androgen concentrations during follow up of adolescents into the third decade of life.  J Clin Endocrinol Metab . 1990;  71 970-974
    CrossrefPubMedGoogle Scholar
  • 70 Venturoli S, Porcu E, Fabbri R. Postmenarchal evolution of endocrine pattern and ovarian aspects in adolescents with menstrual irregularities.  Fertil Steril . 1987;  48 78-85
    PubMedGoogle Scholar
  • 71 Apter D, Butzow T, Laughlin G A. Accelerated 24h LH pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovary syndrome.  J Clin Endocrinol Metab . 1994;  79 119-125
    CrossrefPubMedGoogle Scholar
  • 72 Jakacki R I, Kelch R P, Sauder S E. Pulsatile secretion of luteinizing hormone in children.  J Clin Endocrinol Metab . 1982;  55 453-458
    PubMedGoogle Scholar
  • 73 Marshall J C, Kelch R P. Gonadotropin-releasing hormone: role of pulsatile secretion in the regulation of reproduction.  N Engl J Med . 1986;  315 1459-1468
    PubMedGoogle Scholar
  • 74 Apter D. Serum steroids and pituitary hormones in female puberty: a partly longitudinal study.  Clin Endocrinol (Oxf) . 1980;  12 107-120
    PubMedGoogle Scholar
  • 75 Mitamura R, Yano K, Suzuki N, Ito Y, Makita Y, Okuno A. Diurnal rhythms of luteinizing hormone, follicle-stimulating hormone, testosterone, and estradiol secretion before the onset of female puberty in short children.  J Clin Endocrinol Metab . 2000;  85 1074-1080
    CrossrefPubMedGoogle Scholar